User profiles for Wilfried Eberhardt
 | Wilfried EberhardtInnere Klinik (Tumorforschung), University of Duisburg-Essen Verified email at uni-duisburg-essen.de Cited by 36980 |
[HTML][HTML] The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung …
…, R Rami-Porta, H Asamura, WEE Eberhardt… - Journal of Thoracic …, 2016 - Elsevier
The IASLC Staging and Prognostic Factors Committee has collected a new database of
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …
[HTML][HTML] The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of …
…, R Beyruti, K Kubota, A Turrisi, WEE Eberhardt… - Journal of Thoracic …, 2016 - Elsevier
Introduction Small cell lung cancer (SCLC) is commonly classified as either limited or extensive,
but the Union for International Cancer Control TNM Classification of Malignant Tumours …
but the Union for International Cancer Control TNM Classification of Malignant Tumours …
[HTML][HTML] Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
…, P Baas, L Crinò, WEE Eberhardt… - … England Journal of …, 2015 - Mass Medical Soc
Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …
who have disease progression during or after first-line chemotherapy have limited treatment …
[HTML][HTML] Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label …
…, D Healey, J Brahmer, WEE Eberhardt - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared
with docetaxel in two independent phase III studies in previously treated patients with …
with docetaxel in two independent phase III studies in previously treated patients with …
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the …
…, K Park, F De Marinis, WEE Eberhardt… - The lancet …, 2012 - thelancet.com
Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed
that the addition of cetuximab to first-line chemotherapy significantly improved overall …
that the addition of cetuximab to first-line chemotherapy significantly improved overall …
[HTML][HTML] Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung …
…, DR Spigel, L Crino, WEE Eberhardt… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell lung
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …
cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab …
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
…, E Bajetta, K O'Byrne, F De Marinis, W Eberhardt… - The Lancet, 2009 - thelancet.com
Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor
receptor (EGFR), has the potential to increase survival in patients with advanced non-small-…
receptor (EGFR), has the potential to increase survival in patients with advanced non-small-…
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised …
RS Herbst, Y Sun, WEE Eberhardt, P Germonpré… - The lancet …, 2010 - thelancet.com
Background Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during …
receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during …
[HTML][HTML] The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer
WEE Eberhardt, A Mitchell, J Crowley, H Kondo… - Journal of thoracic …, 2015 - Elsevier
Introduction The aim of this study is to analyze all metastatic (M) categories of the current
tumor, node, and metastasis (TNM) classification of lung cancer with the objective of providing …
tumor, node, and metastasis (TNM) classification of lung cancer with the objective of providing …
[HTML][HTML] The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the …
…, K Chansky, J Crowley, WEE Eberhardt… - Journal of Thoracic …, 2016 - Elsevier
This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …